

## Impact of Socioeconomic Status on Adult Patients with Asthma: A Population-based Cohort Study from UK Primary Care

John Busby, David Price, Riyad Al-Lehebi, Sinthia Bosnic-Anticevich, Job FM van Boven, Benjamin Emmanuel, J Mark FitzGerald, Mina Gaga, Susanne Hansen, Mark Hew, Takashi Iwanaga, Désirée Larenas Linnemann, Bassam Mahboub, Patrick Mitchell, Daniela Morrone, Jonathan Pham, Celeste Porsbjerg, Nicolas Roche, Eileen Wang, Neva Eleangovan, Liam G Heaney



## Background


- Socioeconomic status (SES) is known to affect asthma outcomes such as morbidity, mortality and healthcare utilization
- Suggested reasons for worse asthma outcomes in deprived populations include poorer living conditions and reduced access to specialist care
- UK guidelines: patients with asthma that remains uncontrolled despite standard therapies should be referred to specialists<sup>2</sup>

### Objectives

- 1. Describe the **socioeconomic disparities** in a UK primary care asthma cohort
- 2. Identify the **factors** that influence the impact of SES on asthma outcomes
- 3. Study the impact of SES on **asthma presentations** (e.g., blood eosinophils), **treatment processes** (e.g., respiratory referrals) and **outcomes** (e.g., asthma control and exacerbations)




## **Study design**



















# Impact of SES on asthma presentations, treatment processes and clinical outcomes in UK primary care<sup>a</sup>






Most deprived patients had more uncontrolled asthma and greater likelihood of exacerbations than least deprived patients, but rates of respiratory referrals remained comparable

Sensitivity analysis: Similar rates of respiratory referrals between most and least deprived patients remained among those with ≥2 exacerbations


Clinical implication: More deprived patients may have greater need for specialist reviews and phenotypetargeted treatments like biologics

<sup>a</sup>Adjusted for year, age (5-year groups) and sex; <sup>b</sup>Odds ratio. Patient numbers: n=45,761 for blood eosinophils; n=71,291 for peak flow; n=102,712 for treatment adherent; n=127,040 for asthma review; n=127,040 for respiratory referral; n=40,078 for uncontrolled disease; n=127,040 for any exacerbations SES = Socieeconomic status



Uncontrolled asthma






The impact of increased deprivation on asthma control was greater in patients aged ≥75 years than in those aged <35 years

Odds Ratio



SES = Socioeconomic status Busby J, Price D et al. *J Asthma Allergy* 2021;in press.





#### The impact of increased deprivation on asthma control and exacerbations was greater in ethnic minority groups than in White patients

EMG = Ethnic minority groups; SES = Socioeconomic status Busby J, Price D et al. *J Asthma Allergy* 2021;in press.



- There was evidence of socioeconomic disparities in a UK primary care asthma cohort
- Socioeconomic deprivation has an adverse effect on asthma outcomes
- Most deprived patients were more likely to have worse peak flow, uncontrolled disease or an exacerbation during follow-up than least deprived patients
- Although more deprived patients had more uncontrolled disease, rates of respiratory referrals were similar to those of less deprived patients
- More deprived patients may have greater need for specialist reviews and phenotype-targeted treatments like biologics
- Age and ethnicity influence the magnitude of SES's impact on asthma outcomes
  - The impact of increased deprivation on asthma control was more pronounced in older patients versus younger patients, and in ethnic minority groups versus White patients
- Interventions to resolve socioeconomic disparities should be explored, both in the UK and globally, to improve overall asthma outcomes





- We would like to thank all patients and collaborators who contributed to this academic research study, which was prioritized by ISAR.
- This research study was funded and delivered by the Observational and Pragmatic Research Institute Pte Ltd (OPRI). Optimum Patient Care Global received partial funding from AstraZeneca Ltd to support dataset creation.
- OPCRD has been reviewed and ethically approved by the NHS Health Research Authority to hold and process anonymized data as part of service delivery (Research Ethics Committee reference: 15/EM/0150). Ethical approval for this research study was granted by the ADEPT committee (ADEPT0120). The study was designed, implemented and registered in accordance with the criteria of ENCePP (EUPAS32482).



